How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
about
Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysisBenzodiazepines for schizophreniaMaintenance treatment with antipsychotic drugs for schizophreniaEfficacy of antimanic treatments: meta-analysis of randomized, controlled trialsPharmacologic treatment of schizophreniaAerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health TreatmentTowards medication-enhancement of cognitive interventions in schizophreniaProfile of minocycline and its potential in the treatment of schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewPublication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseThe Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosisA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic MiceMotive-oriented therapeutic relationship building for patients diagnosed with schizophrenia.Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometryClinical utility of the risperidone formulations in the management of schizophrenia.Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis.Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventionsNeuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research.Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Packages of care for schizophrenia in low- and middle-income countries.Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directionsAn Integrative Perspective on the Role of Dopamine in SchizophreniaNonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.Recent advances in understanding schizophreniaRevisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.Possible role of glia in cognitive impairment in schizophrenia.Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial.Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS).World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trialMethodological issues in current antipsychotic drug trials.Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
P2860
Q22251382-6C32D2EA-E347-4EED-93F0-C5EEE476233DQ24197501-4695807B-5654-462B-B3F9-2DC5ACF32D76Q24197902-2DE6362F-7579-4025-A822-2DE5494AB0B3Q24601815-AF0B726A-D5DA-4AE8-9583-202B2275F3E8Q24604457-09E41751-E61C-44B7-A9D2-67295871218DQ26741515-53510306-EF19-4E0C-9E0A-C926706DCFC9Q26860777-9A057FD2-0FE4-43C8-AC84-77D2AEC2B31EQ26864400-5EF6C2E1-221C-4C6B-AA0A-FEA083785882Q28079821-58063FEF-DC1C-44E1-8F39-3A5B78828C15Q28481584-912F35CF-79FC-4DD0-9C36-C6391679D830Q28545094-2A01EC86-02A6-4E1D-945D-20BC69B967DAQ30353864-9DC95AF7-EBBF-463E-9F94-15F2C043E406Q30364693-FC088F55-F60F-4518-88B7-5AC54A7D649EQ30402711-E352A68E-A955-441A-8AE7-2138C2CD54A0Q30404054-2E44C44F-CF2D-4FEF-AC10-43B8BACD7884Q30429721-16BBEA33-EA55-4C94-B21D-B963AE23830CQ30435857-421A55CA-B21D-4B0A-9BF5-52709F7DA48AQ30444600-9F2459B7-7037-4ED2-9A6F-CFCE0D807A7EQ30582343-2AD61BC2-8706-4C05-9EB4-E3E6C7EE28A9Q30590794-06302E22-C6E2-495F-BAE1-82C11C95B54CQ33511434-1DF6783A-58DF-4AB6-AB5E-077775A40C75Q33631663-54CFE054-1ABA-4BFF-9951-46243F93A6D4Q33839379-F89F7D8D-5542-43E9-B8A2-18AF4B37DC94Q33857710-50F18AB8-C243-4740-8656-80FA8DACABD3Q33879147-FE0E4C29-B2C7-4870-A7BE-FCDB6A69351FQ33942094-0CFABE76-7D0E-4C78-AB70-C2151961D389Q34022882-08E9D388-943F-49FD-858C-B807CDBF69C9Q34032500-4D3E39EF-86F3-4ABE-BDE7-F74E3358187AQ34155219-2D874FFB-77E2-4662-AB35-13E8709386E5Q34224372-FD0852C2-7868-4F4D-B85D-DCC10FA6120BQ34266750-E76AD300-9AEB-4A42-B8B7-73B5A76DD69CQ34286688-AFBD7479-DBA7-4008-8820-8BD59A4A72CAQ34311294-8D997F2C-719F-4D71-A633-1C415C63C691Q34315836-CCCB1A33-7C1F-4EC8-97EB-E0D50AA4403CQ34486230-A1729F27-8408-46C7-ACE1-B998E3B57ECDQ34587745-31A5242A-6DD4-47D5-B5BB-CCF0574A66C4Q34604423-C4DA6004-C25D-4FD4-9C5F-592E84218D0DQ34620095-C13DB2D1-7632-4CC4-B4BF-5C620CDC6E5EQ34628304-7022CF88-3A12-4965-A7A4-1F44408A683EQ34640811-CA6CE270-1EC2-405A-924B-9AA612A7B4BE
P2860
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
How effective are second-gener ...... of placebo-controlled trials.
@ast
How effective are second-gener ...... of placebo-controlled trials.
@en
How effective are second-gener ...... of placebo-controlled trials.
@nl
type
label
How effective are second-gener ...... of placebo-controlled trials.
@ast
How effective are second-gener ...... of placebo-controlled trials.
@en
How effective are second-gener ...... of placebo-controlled trials.
@nl
prefLabel
How effective are second-gener ...... of placebo-controlled trials.
@ast
How effective are second-gener ...... of placebo-controlled trials.
@en
How effective are second-gener ...... of placebo-controlled trials.
@nl
P2093
P2860
P356
P1433
P1476
How effective are second-gener ...... of placebo-controlled trials.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.MP.4002136
P407
P577
2008-01-08T00:00:00Z